Prime Medicine, Inc. Preferred Stock Dividends, Income Statement Impact
Prime Medicine, Inc. (PRME) reported Preferred Stock Dividends, Income Statement Impact of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-01.
Discontinued › Expense Statement › Operating Expenses
us-gaap:PreferredStockDividendsIncomeStatementImpact · last filed 2024-03-01
- Prime Medicine, Inc. preferred stock dividends, income statement impact for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- Prime Medicine, Inc. preferred stock dividends, income statement impact for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- Prime Medicine, Inc. preferred stock dividends, income statement impact for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- Prime Medicine, Inc. preferred stock dividends, income statement impact for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- Prime Medicine, Inc. preferred stock dividends, income statement impact for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Prime Medicine, Inc. preferred stock dividends, income statement impact for fiscal 2022 was $20.19M, a 16.83% increase from fiscal 2021.
- Prime Medicine, Inc. preferred stock dividends, income statement impact for fiscal 2021 was $17.28M.
- Prime Medicine, Inc. preferred stock dividends, income statement impact for fiscal 2020 was $0.00.
| Period end | Preferred Stock Dividends, Income Statement Impact 3 month | Preferred Stock Dividends, Income Statement Impact 6 month | Preferred Stock Dividends, Income Statement Impact 9 month | Preferred Stock Dividends, Income Statement Impact 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $0.00 derived: sum of 2 quarters · filed 2024-03-01 | $0.00 derived: sum of 3 quarters · filed 2024-03-01 | $0.00 10-K · filed 2024-03-01 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-03 | $0.00 derived: sum of 2 quarters · filed 2023-11-03 | $0.00 10-Q · filed 2023-11-03 | $1.31M derived: sum of 4 quarters · filed 2024-03-01 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-07 | $0.00 10-Q · filed 2023-08-07 | $1.31M derived: sum of 3 quarters · filed 2024-03-01 | $7.68M derived: sum of 4 quarters · filed 2024-03-01 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-11 | $1.31M derived: sum of 2 quarters · filed 2024-03-01 | $7.68M derived: sum of 3 quarters · filed 2024-03-01 | $13.97M derived: sum of 4 quarters · filed 2024-03-01 |
| 2022-12-31 | $1.31M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $7.68M derived: sum of 2 quarters · filed 2024-03-01 | $13.97M derived: sum of 3 quarters · filed 2024-03-01 | $20.19M 10-K · filed 2024-03-01 |
| 2022-09-30 | $6.36M 10-Q · filed 2023-11-03 | $12.65M derived: sum of 2 quarters · filed 2023-11-03 | $18.88M 10-Q · filed 2023-11-03 | $25.24M derived: sum of 4 quarters · filed 2023-11-03 |
| 2022-06-30 | $6.29M 10-Q · filed 2023-08-07 | $12.52M 10-Q · filed 2023-08-07 | $18.88M derived: sum of 3 quarters · filed 2023-08-07 | $25.24M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $6.22M 10-Q · filed 2023-05-11 | $12.59M derived: sum of 2 quarters · filed 2023-05-11 | $18.95M derived: sum of 3 quarters · filed 2023-05-11 | |
| 2021-12-31 | $6.36M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $12.72M derived: sum of 2 quarters · filed 2023-03-09 | $17.28M 10-K · filed 2023-03-09 | |
| 2021-09-30 | $6.36M 10-Q · filed 2022-11-14 | $10.92M 10-Q · filed 2022-11-14 | ||
| 2020-12-31 | $0.00 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |